GRA worked in partnership with a European vaccine development company to lead an application for a £1 million SBRI contract funded by the UK’s Department of Health. The funds were intended for the clinical and formulation development of a Zika vaccine.
GRA worked with the vaccine company to assemble a business case for the development of a Zika vaccine and justify how the funding could accelerate their program into phase I clinical trials. This case was put forward to the SBRI review panel. The application was described as ‘exemplary’ by the review panel and after a final interview panel, the application was confirmed as successful in June 2016. The project is being performed over a period of 18 months. GRA successfully helped lead the application to raise almost £1 million in non-dilutional funding to develop the vaccine. GRA is also project managing the contract. Read the press release here.
Complete your details and we’ll send you regular updates via our newsletter.
Need to understand some element of the biopharma industry or looking for a particular template?